KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Halozyme Therapeutics (HALO) over the last 10 years, with Q3 2025 value amounting to $43.7 million.

  • Halozyme Therapeutics' Tax Provisions rose 5543.43% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.5 million, marking a year-over-year increase of 7171.62%. This contributed to the annual value of $113.0 million for FY2024, which is 6938.79% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Tax Provisions stood at $43.7 million, which was up 5543.43% from $39.8 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Tax Provisions registered a high of $43.7 million during Q3 2025, and its lowest value of -$142.5 million during Q3 2021.
  • Over the past 5 years, Halozyme Therapeutics' median Tax Provisions value was $15.8 million (recorded in 2023), while the average stood at $9.6 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first tumbled by 22626031.75% in 2021, then surged by 1253103.45% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Tax Provisions stood at -$12.0 million in 2021, then surged by 209.44% to $13.1 million in 2022, then grew by 20.61% to $15.8 million in 2023, then surged by 160.99% to $41.2 million in 2024, then increased by 6.14% to $43.7 million in 2025.
  • Its last three reported values are $43.7 million in Q3 2025, $39.8 million for Q2 2025, and $25.7 million during Q1 2025.